Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.58 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.58 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.58 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582997 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30583012 | 0.92 | ADORA1 (0.62) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL15329251 | 0.92 | ADORA1 (0.62) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL2217172 | 0.92 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL888085 | 0.92 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29384615 | 0.92 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL8325770 | 0.91 | ADORA1 (0.85) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30670292 | 0.90 | ADORA1 (0.76) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL17438017 | 0.90 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL24264106 | 0.89 | ADORA1 (0.61) | ADORA1DNPH1PRKAB2TRPM2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745239-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | Rigerna Therapeutics Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2025026228-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | 苏州炫景生物科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| EP-4745239-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | Rigerna Therapeutics Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12600965-B2 | Modified double stranded oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12503699-B2 | Compositions and methods for silencing UGT1a1 gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12460206-B2 | PCSK9 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250333737-A1 | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160017335-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-20160017330-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-9133461-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9127274-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150111841-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-04-23 | — | — | US | disclosed |
| US-20130317080-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130317081-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2013-11-28 | — | — | US | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | EIF2AK2, DCLRE1B, DNASE1L3 | ADORA1 3419/4885DNPH1 4021/4885PRKAB2 119/4885 |
| US-12600965-B2 | Modified double stranded oligonucleotide | NSUN2, EIF2AK2, ADAR | ADORA1 1034/4885DNPH1 4193/4885PRKAB2 463/4885 |
| US-12460206-B2 | PCSK9 iRNA compositions and methods of use thereof | PCSK9, LDLR, RNASE1 | ADORA1 3722/4885DNPH1 3890/4885PRKAB2 1359/4885 |
| US-20160017335-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PCSK9, LDLR, RNASE1 | ADORA1 3722/4885DNPH1 3890/4885PRKAB2 1359/4885 |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, APOL1, LDLR | ADORA1 2685/4885DNPH1 3497/4885PRKAB2 2902/4885 |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PLG, PLAU, PLAUR | ADORA1 1543/4885DNPH1 3312/4885PRKAB2 1805/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | ADORA1 1114/4885DNPH1 3183/4885PRKAB2 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.